title: [News in the medical treatment of breast cancer].
abstract: During the last decade, except for breast cancer, few "solid" tumours have benefited from significant progress in systemic treatment able to reduce the progression of metastases in advanced disease or to eradicate possible micro-metastases in the adjuvant situation. This review aims to guide the reader along the paths of the progress made in hormonotherapy, chemotherapy and targeted molecular therapy. For each category, the authors will attempt to estimate the impact of the therapeutic advances upon day-to-day clinical practice.
authors.affiliation: Unité de chimiothérapie, Institut Jules-Bordet, 1, rue Heger-Bordet, 1000 Bruxelles, Belgique.
authors.forename: Martine
authors.initials: M
authors.lastname: Piccart
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Dochy
authors.forename: Fatima
authors.initials: F
authors.lastname: Cardoso
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D013629:Tamoxifen / Q000627:therapeutic use; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D000068878:Trastuzumab